The primary objective of the study is to identify which features of platelet activation promote the inflammatory response that underlies the progression from NAFL to NASH.
Therefore, the investigators plan:
To characterize and compare the platelet inflammatory phenotype in NAFL vs NASH patients
To study if and how the signaling pathways controlled by ITAM/ITIM-coupled receptors is dysregulated in NAFL vs NASH As a secondary objective the investigators will analyze platelet activation and inflammatory response in a subset of NAFL and NASH patients after 2, 4 and 6 hours from consumption of a high fat meal to test if and how the platelet inflammatory phenotype is promoted by post-prandial plasma lipids.

开始日期2021-12-06

申办/合作机构

Sapienza University of Rome

[+1]

NCT00062348 / Completed临床1期IIT

B-Uptake In Different Tumours Using The Boron Compounds BSH And BPA

RATIONALE: Diagnostic procedures using boronophenylalanine-fructose complex (BPA-F) and/or sodium borocaptate (BSH) to detect the presence of boron in tumor cells may help determine whether patients who have thyroid cancer, head and neck cancer, or liver metastases may benefit from boron neutron capture therapy.
PURPOSE: This phase I trial is studying the side effects of giving BPA-F and/or BSH before surgery to detect boron uptake in tissues of patients with primary, metastatic, or recurrent thyroid cancer, head and neck cancer, or liver metastases from colorectal cancer.

开始日期2003-04-01

申办/合作机构

Eortc

NCT00004015 / Completed临床1期IIT

Postoperative Treatment of Glioblastoma With BNCT at the Petten Irradiation Facility

RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue.
PURPOSE: This phase I trial is studying the side effects and best dose of boron neutron capture therapy following surgery in treating patients with glioblastoma multiforme removed during surgery.

开始日期2002-06-01

申办/合作机构

Eortc

100 项与 Sodium borocaptate 相关的临床结果

登录后查看更多信息

100 项与 Sodium borocaptate 相关的转化医学

登录后查看更多信息

100 项与 Sodium borocaptate 相关的专利（医药）

登录后查看更多信息

386

项与 Sodium borocaptate 相关的文献（医药）

2025-01-01·Journal of Ethnopharmacology

Simiao Wan attenuates high-fat diet-induced hyperlipidemia in mice by modulating the gut microbiota–bile acid axis

Article

作者: Xia, Ting ; Ding, Mengze ; Tan, Xiaomei ; Wang, Kexin ; Xu, Wenjie ; He, Wen

ETHNOPHARMACOLOGICAL RELEVANCEHyperlipidemia is a lipid metabolism disorder and a risk factor for obesity, diabetes, and coronary heart disease. It occurs mostly in the old adults; however, its incidence rate is increasing annually and there is a trend towards younger adults. Current clinical drugs for treating hyperlipidemia have multiple side effects. Therefore, it is necessary to develop safe and effective drugs from natural products to prevent and treat hyperlipidemia. Simiao Wan (SMW) is a classic Chinese medicine prescription first recorded in the Cheng Fang Bian Du of the Qing Dynasty. Studies have shown that SMW has excellent efficacy in metabolic diseases, which can effectively improve hyperlipidemia combined with other metabolic diseases. However, its underlying mechanism in hyperlipidemia treatment is yet to be clarified.AIM OF THE STUDYTo investigate the hypolipidemic effect of SMW on hyperlipidemic mice and explore whether the gut microbiota-bile acid (BA) axis is the potential mechanism.MATERIALS AND METHODSA hyperlipidemic mouse model was established using a high-fat diet (HFD), and the hypolipidemic effect of SMW was detected in vivo. We performed 16S ribosomal RNA sequencing and BA metabolism analysis to explore the hypolipidemic mechanisms of SMW. Western blotting was conducted to detect the expression of proteins involved in the gut microbiota-bile acid axis to determine the potential lipid-lowering pathway.RESULTSExcessive obesity in hyperlipidemic mice was alleviated after 8 weeks of SMW treatment. The total cholesterol and low-density lipoprotein cholesterol levels decreased significantly, whereas high-density lipoprotein cholesterol levels increased. SMW also reduced hepatic lipid and inguinal white adipose tissue accumulation in HFD-induced hyperlipidemic mice. Furthermore, intestinal bile saline hydrolase (BSH) level, associated with BA excretion, decreased. Meanwhile, SMW decreased the abundance of BSH-enriched microbes in hyperlipidemic mice. SMW increased the intestinal conjugated-BAs contents in hyperlipidemic mice, especially tauro-β-muricholic acid and tauro-ursodeoxycholic acid, which are ileac farnesoid X receptor (FXR) antagonists. Inhibited intestinal FXR signaling with SMW was accompanied by a decreased expression of intestinal fibroblast growth factor 15 and the activation of hepatic FXR, which promoted hepatic cholesterol conversion to BA.CONCLUSIONSMW indirectly attenuated HFD-induced hyperlipidemia in mice by regulating the gut microbiota-BA axis. Our results provide a pharmacological basis for SMW treating hyperlipidemia and suggest a new idea for developing lipid-lowering drugs.

2024-11-01·Journal of Microbiological Methods

Fermentation dynamics of bile salt hydrolase production in Heyndrickxia coagulans ATCC 7050 and Lactiplantibacillus plantarum ATCC 10012: Addressing ninhydrin assay limitations with a novel HPTLC–MS method

Article

作者: Annapure, Uday S. ; Annapure, Uday S ; Nair, Pratisha P. ; Nair, Pratisha P

Bile salt hydrolase (BSH), a pivotal enzyme in cholesterol management, holds significant promise in both human and animal subjects. This study investigated the effect of fermentation dynamics in Heyndrickxia coagulans ATCC 7050 and Lactiplantibacillus plantarum ATCC 10012 to enhance BSH production. Cultivation of cultures in MRS and M17 media revealed that MRS medium enhanced BSH production by 235.98 % in H. coagulans ATCC 7050 and 147.37 % in L. plantarum ATCC 10012, compared to M 17 medium. Additionally, varying oxygen concentration levels indicated that H. coagulans ATCC 7050 exhibited its minimum doubling time of 79.8 ± 0.64 min in anaerobic conditions, whereas L.plantarum ATCC 10012 demonstrated its minimum doubling time of 85.5 ± 1.2 min under microaerophilic conditions. However, their highest BSH activity was observed during the stationary phase under anaerobic conditions, yielding 17.14 ± 0.78 U/mL by H. coagulans ATCC 7050 and 19.04 ± 0.81 U/mL by L.plantarum ATCC 10012. Furthermore, it was observed that both organisms did not retain BSH within their cells. BSH activity was assessed using ninhydrin assay that detected free taurine liberated from sodium taurocholate. However, ninhydrin can yield false-positive results owing to its interaction with other free amino acids. To subjugate this limitation, the study introduced a novel and sensitive HPTLC-MS method capable of accurately detecting taurine. By comprehending fermentation dynamics and selecting appropriate conditions, BSH production increased 2.1-fold in both organisms. These findings illuminate critical insights, offering a pathway for novel strategies to enhance the BSH-producing capabilities of these LAB strains.

2024-11-01·Life Sciences

Identification of protein partners for small molecules reshapes the understanding of nonalcoholic steatohepatitis and drug discovery

Review

作者: Wang, Yibing ; Wang, Danyi

AIMSNonalcoholic steatohepatitis (NASH) is the severe subtype of nonalcoholic fatty diseases (NAFLD) with few options for treatment. Patients with NASH exhibit partial responses to the current therapeutics and adverse effects. Identification of the binding proteins for the drugs is essential to understanding the mechanism and adverse effects of the drugs and fuels the discovery of potent and safe drugs. This paper aims to critically discuss recent advances in covalent and noncovalent approaches for identifying binding proteins that mediate NASH progression, along with an in-depth analysis of the mechanisms by which these targets regulate NASH.MATERIALS AND METHODSA literature search was conducted to identify the relevant studies in the database of PubMed and the American Chemical Society. The search covered articles published from January 1990 to July 2024, using the search terms with keywords such as NASH, benzophenone, diazirine, photo-affinity labeling, thermal protein profiling, CETSA, target identification.KEY FINDINGSThe covalent approaches utilize drugs modified with diazirine and benzophenone to covalently crosslink with the target proteins, which facilitates the purification and identification of target proteins. In addition, they map the binding sites in the target proteins. By contrast, noncovalent approaches identify the binding targets of unmodified drugs in the intact cell proteome. The advantages and limitations of both approaches have been compared, along with a comprehensive analysis of recent innovations that further enhance the efficiency and specificity.SIGNIFICANCEThe analyses of the applicability of these approaches provide novel tools to delineate NASH pathogenesis and promote drug discovery.

472

项与 Sodium borocaptate 相关的新闻（医药）

2024-10-30

·摩熵医药

诺华Q3 财报：销售额增长 18%，降脂药Leqvio翻倍增长！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 10月29日，诺华公布2024Q3业绩，第三季度收入128.23亿美元，同比增长10%。前9个月总收入371.64亿美元，同比增长11%。按净利润算，诺华Q3净收入为31.85亿美元（+121%），前三季度净收入为91.19亿美元（+62%）。营业收入 36 亿美元，同比增长 123%。其中，中国区 Q3 净销售额 10 亿美元，同比增长 18%。截图来源：诺华2024Q3财报PPT 从具体业务领域来看，心血管-肾脏-代谢、免疫、神经科学和肿瘤业务前三季度的销售收入分别为61.73亿美元（+35%）、68.86亿美元（+22%）、34.59亿美元（+31%）和108.08亿美元（+15%）。诺华的多个重磅产品均保持着稳健增长，如Entresto（沙库巴曲缬沙坦）、Cosentyx（司库奇尤单抗）、Kesimpta（奥法妥木单抗）；部分产品实现了高速增长，如Kisqali（瑞波西利）、Pluvicto（lutetium Lu 177 vipivotide tetraxetan）、Leqvio（英克司兰）、Scemblix（阿思尼布）。诺华2024前三季度TOP20畅销药物截图来源：诺华2024Q3财报新闻稿在心血管-肾脏-代谢领域，诺华的两款革命性药物Entresto（沙库巴曲缬沙坦）和Leqvio（英克司兰）分别贡献了56.42亿美元（+30%）和5.31亿美元（+130%）的收入。 Entresto在明年会面临较大威胁，一方面诺华预计2025年中期Entresto的仿制药将进入美国市场，另一方面Entresto进入了美国第一轮医保谈判降价名单，价格降幅达到53%（2026年开始执行）。截图来源：诺华2024Q3财报PPT Leqvio（英克司兰）虽然也承受着来自依洛尤单抗、托莱西单抗等PCSK9单抗的竞争压力，但增长势头良好。诺华仍然在继续扩展Leqvio的应用边界，已计划提交该药物用于降低低或中等ASCVD风险患者的LDL-C水平的上市申请。截图来源：诺华2024Q3财报PPT 此外，诺华第三季度财报显示，收购MorphoSys公司五个月后，记录8亿美元减值。周二还披露三项二期研究：BCMA细胞疗法durcabtagene autoleucel治多发性骨髓瘤，候选药物XXB750治高血压和心力衰竭，IL-17抑制剂CMK389治肺肉瘤病。目前公司共有105条研发管线截图来源：诺华网 END 近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，了解更多品牌升级详情！

财报并购细胞疗法

2024-10-30

·摩熵医药

10亿集采大品种，2家药企同日获批！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 10月29日，据NMPA官网最新公示，重庆药友制药和山西普德药业2家药企提交的3类仿制药注射用盐酸罗沙替丁醋酸酯同日获批。至此，该品种已形成14+1家企业的竞争格局，市场竞争愈发白热化。截图来源：NMPA 盐酸罗沙替丁醋酸酯是一款组胺H2受体拮抗剂，主要是治疗与胃酸分泌相关疾病的药物，临床上用于上消化道出血（由消化性溃疡，急性应激性溃疡，出血性胃炎等引起）的低危患者。近年来，注射用盐酸罗沙替丁醋酸酯销售规模持续上涨，据摩熵医药数据库显示，注射用盐酸罗沙替丁醋酸酯在2023年全国院内市场的销售额逼近10亿元。截图来源：摩熵医药（原药融云）全国医院销售数据库此前，国内有12家企业拥有注射用盐酸罗沙替丁醋酸酯生产批文。在仿制药布局方面，注射用盐酸罗沙替丁醋酸酯有国药集团国瑞药业、浙江华海药业、海南倍特药业等17家药企提交了仿制申请，均在审评审批中。截图来源：摩熵医药（原药融云）中国药品审评数据库近期，国家发布了第十批集中采购报量目录，其中包含了注射用盐酸罗沙替丁醋酸酯。截至目前，注射用盐酸罗沙替丁醋酸酯已有包括重庆药友制药、瑞阳制药、扬子江药业集团江苏紫龙药业、四川汇宇制药、山西普德药业等在内的14家国内药企过评，形成了14+1的企业竞争格局，市场竞争态势日趋白热化。截图来源：摩熵医药（原药融云）过评药品汇总数据库 2024年至今，重庆药友制药有阿立哌唑口崩片、利培酮口崩片、甲磺酸仑伐替尼胶囊、盐酸依匹斯汀胶囊、盐酸鲁拉西酮片等21个品种过评，其中盐酸依匹斯汀胶囊为首家过评品种。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，了解更多品牌升级详情！

申请上市医药出海一致性评价上市批准

2024-10-30

·摩熵医药

阿斯利康1类新药在中国获批临床！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 10月29日，据CDE官网公示，阿斯利康的AZD5492在中国获批临床，拟用于治疗复发性或难治性B细胞恶性肿瘤。截图来源：CDE AZD5492是一款CD20×TCR×CD8三特异性抗体，为CD8引导的T细胞衔接器剂，首次在中国获批临床。B细胞恶性肿瘤源于B淋巴细胞异常增殖，包括多发性骨髓瘤、淋巴瘤等。截图来源：摩熵医药全球药物研发数据库 2024年8月14日AZD5492在中国申报临床，它是一种不对称三特异性IgG1抗体，含两抗CD20 Fab结构域、一TCR结合VHH结构域和一CD8共受体结合VHH结构域。抗CD20抗体常用于B细胞疾病治疗。截图来源：摩熵医药全球药物研发数据库在2024欧洲血液学协会年会上，AZD5492治疗B型非霍奇金淋巴瘤的临床前研究数据被公布，显示其通过优先连接CD8+T细胞诱导B细胞杀伤，减少CD4+T细胞活化，有望提高B细胞淋巴瘤治疗效果。目前研发现状，AZD5492在美国、加拿大、澳大利亚处于临床前阶段。截图来源：摩熵医药全球药物研发数据库此次AZD5492在中国获得临床批准，标志着这款新药即将在中国启动临床研究。 END 近期热门资源获取后台回复关键词“深度报告”，获取价值18600元，报告大礼包后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复“GLP-1深度报告”，获取完整《GLP-1产业现状与未来发展》PDF版。后台回复“中国 I 类新药”，获取完整《中国 I 类新药靶点》PDF版。后台回复“NAFLD/NASH”，获取完整《NAFLD/NASH报告》PDF版。后台回复“AI+制药”，获取完整《中国AI制药企业白皮书》PDF版。后台回复“XXG”，获取完整《中国心血管系统药物分析报告》PDF版。后台回复“FZZJ”，获取完整《基于剂型改良的复杂注射剂分析》PDF版。后台回复“药品进出口”，获取完整《中国药品进出口白皮书》深度报告-PDF版。联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，了解更多品牌升级详情！

临床申请临床1期ASH会议

100 项与 Sodium borocaptate 相关的药物交易

登录后查看更多信息